Medications for obesity management: Effectiveness and value: A summary from the Institute for Clinical and Economic Review’s New England Comparative Effectiveness Public Advisory Council
Open accessThe claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Most studies find that GLP-1s, even at currently discounted prices, do not meet accepted thresholds for cost-effective therapy, such as less than $150,000 per quality-adjusted life year gained.
“Considering cost‐effectiveness, that is, health gained per dollar spent, most studies find that GLP‐1s, even at currently discounted prices, do not meet accepted thresholds for cost‐effective therapy (e.g., <$150,000 per quality‐adjusted life year gained).”
From Nutritional priorities to support <scp>GLP</scp> ‐1 therapy for obesity: A joint Advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society (2025) · cites this paper as [83]
The Policy Discussion says that, at prices net of rebates, semaglutide and liraglutide exceeded commonly accepted cost-effectiveness thresholds. The Long-Term Cost-Effectiveness section reports $237,000 and $483,000 per QALY gained, respectively, versus lifestyle modification. These findings support the claim for this paper’s analysis, but the paper does not establish that most studies reach that conclusion. (LLM, conf=0.85)
Experimental — accuracy not yet measuredThese risk equations are also applied in cost effectiveness modelling for healthcare coverage evaluations, such as by the Institute for Clinical and Economic Review.
“These risk equations are also applied in cost effectiveness modelling for healthcare coverage evaluations, such as by the Institute for Clinical and Economic Review (ICER).29”
From Tirzepatide compared with semaglutide and 10-year cardiovascular disease risk reduction in obesity: <i>post-hoc</i> analysis of the SURMOUNT-5 trial (2025) · cites this paper as [29]
In nonindustry-sponsored analyses, net costs per quality-adjusted life year for GLP-1s have ranged from $237,000 to $483,000.
“In nonindustry‐sponsored analyses, net costs per quality‐adjusted life year have ranged from $237,000 to $483,000 [83], with low cost‐effectiveness related to plateauing of weight benefits but continued high costs of treatment, as well as weight regain following any cessation of use.”
At current prices in the US, the cost effectiveness of semaglutide or liraglutide in patients without type 2 diabetes exceeded commonly used cost effectiveness thresholds.
“The model also reported that, at current prices in the US, the cost effectiveness of semaglutide or liraglutide in patients without type 2 diabetes exceeded commonly used cost effectiveness thresholds.”
From Effectiveness and safety of drugs for obesity (2024) · cites this paper as [143]
Phentermine-topiramate in addition to lifestyle modification was the most cost effective option, particularly when prescribed generically.
“Finally, another model found that phentermine-topiramate in addition to lifestyle modification was the most cost effective option, particularly when prescribed generically.143”
From Effectiveness and safety of drugs for obesity (2024) · cites this paper as [143]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
General Cardiovascular Risk Profile for Use in Primary Care: The Framingham Heart Study
D’Agostino, R. B., Vasan, R. S., Pencina, M. J., Wolf, P. A., Cobain, M., Massaro, J. M., & Kannel, W. B. (2008) · Circulation · doi:10.1161/circulationaha.107.699579 · Cited by 7,491 · see citing works
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2032183 · Cited by 5,205 · see citing works
A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management
Pi-Sunyer, X., Astrup, A., Fujioka, K., Greenway, F., Halpern, A., Krempf, M., Lau, D. C. W., le Roux, C. W., Violante Ortiz, R., Jensen, C. B., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411892 · Cited by 2,724 · see citing works
Projected U.S. State-Level Prevalence of Adult Obesity and Severe Obesity
Ward, Z. J., Bleich, S. N., Cradock, A. L., Barrett, J. L., Giles, C. M., Flax, C., Long, M. W., & Gortmaker, S. L. (2019) · New England Journal of Medicine · doi:10.1056/nejmsa1909301 · Cited by 2,009 · see citing works
Blundell, J. E., Baker, J. L., Boyland, E. J., Blaak, E. E., Charzewska, J., Henauw, S. D., Frühbeck, G., González‐Gross, M., Hebebrand, J., Holm, L., et al. (2017) · Obesity Facts · doi:10.1159/000455952 · Cited by 1,980 · see citing works
Garvey, W. T., Mechanick, J. I., Brett, E. M., Garber, A. J., Hurley, D. L., Jastreboff, A. M., Nadolsky, K., Pessah-Pollack, R., & Plodkowski, R. (2016) · Endocrine Practice · doi:10.4158/ep161365.gl · Cited by 1,914 · see citing works
Mechanisms, Pathophysiology, and Management of Obesity
Heymsfield, S. B., & Wadden, T. A. (2017) · New England Journal of Medicine · doi:10.1056/nejmra1514009 · Cited by 1,867 · see citing works
Obesity in adults: a clinical practice guideline
Wharton, S., Lau, D. C. W., Vallis, M., Sharma, A. M., Biertho, L., Campbell-Scherer, D., Adamo, K., Alberga, A., Bell, R., Boulé, N., et al. (2020) · Canadian Medical Association Journal · doi:10.1503/cmaj.191707 · Cited by 1,506 · see citing works
Davies, M., Færch, L., Jeppesen, O. K., Pakseresht, A., Pedersen, S. D., Perreault, L., Rosenstock, J., Shimomura, I., Viljoen, A., Wadden, T. A., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00213-0 · Cited by 1,419 · see citing works
Benefits and Risks of Bariatric Surgery in Adults: A Review
Arterburn, D. E., Telem, D. A., Kushner, R. F., & Courcoulas, A. P. (2020) · JAMA · doi:10.1001/jama.2020.12567 · Cited by 1,251 · see citing works
Davies, M. J., Bergenstal, R., Bode, B., Kushner, R. F., Lewin, A., Skjøth, T. V., Andreasen, A. H., Jensen, C. B., DeFronzo, R. A., & for the NN8022-1922 Study Group (2015) · JAMA · doi:10.1001/jama.2015.9676 · Cited by 1,198 · see citing works
Wadden, T. A., Bailey, T. S., Billings, L. K., Davies, M., Frias, J. P., Koroleva, A., Lingvay, I., O’Neil, P. M., Rubino, D. M., Skovgaard, D., et al. (2021) · JAMA · doi:10.1001/jama.2021.1831 · Cited by 1,114 · see citing works
Gadde, K. M., Allison, D. B., Ryan, D. H., Peterson, C. A., Troupin, B., Schwiers, M. L., & Day, W. W. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60205-5 · Cited by 1,064 · see citing works
Greenway, F. L., Fujioka, K., Plodkowski, R. A., Mudaliar, S., Guttadauria, M., Erickson, J., Kim, D. D., & Dunayevich, E. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60888-4 · Cited by 1,036 · see citing works
Bray, G. A., Frühbeck, G., Ryan, D. H., & Wilding, J. P. H. (2016) · The Lancet · doi:10.1016/s0140-6736(16)00271-3 · Cited by 1,036 · see citing works
Rubino, D. M., Greenway, F. L., Khalid, U., O’Neil, P. M., Rosenstock, J., Sørrig, R., Wadden, T. A., Wizert, A., Garvey, W. T., STEP 8 Investigators, et al. (2022) · JAMA · doi:10.1001/jama.2021.23619 · Cited by 995 · see citing works
on behalf of the NN8022-1923 Investigators, Wadden, T. A., Hollander, P., Klein, S., Niswender, K., Woo, V, Hale, P. M., & Aronne, L. (2013) · International Journal of Obesity · doi:10.1038/ijo.2013.120 · Cited by 842 · see citing works
Apovian, C. M., Aronne, L., Rubino, D., Still, C., Wyatt, H., Burns, C., Kim, D., Dunayevich, E., & for the COR‐II Study Group (2013) · Obesity · doi:10.1002/oby.20309 · Cited by 720 · see citing works
Allison, D. B., Gadde, K. M., Garvey, W. T., Peterson, C. A., Schwiers, M. L., Najarian, T., Tam, P. Y., Troupin, B., & Day, W. W. (2012) · Obesity · doi:10.1038/oby.2011.330 · Cited by 711 · see citing works
on behalf of the SCALE study group, Blackman, A., Foster, G. D., Zammit, G., Rosenberg, R., Aronne, L., Wadden, T., Claudius, B., Jensen, C. B., & Mignot, E. (2016) · International Journal of Obesity · doi:10.1038/ijo.2016.52 · Cited by 583 · see citing works
US Preventive Services Task Force, Curry, S. J., Krist, A. H., Owens, D. K., Barry, M. J., Caughey, A. B., Davidson, K. W., Doubeni, C. A., Epling, J. W., Grossman, D. C., et al. (2018) · JAMA · doi:10.1001/jama.2018.13022 · Cited by 563 · see citing works
Wadden, T. A., Foreyt, J. P., Foster, G. D., Hill, J. O., Klein, S., O'Neil, P. M., Perri, M. G., Pi‐Sunyer, F. X., Rock, C. L., Erickson, J. S., et al. (2011) · Obesity · doi:10.1038/oby.2010.147 · Cited by 558 · see citing works
Moyer, V. A., & on behalf of the U.S. Preventive Services Task Force* (2012) · Annals of Internal Medicine · doi:10.7326/0003-4819-157-5-201209040-00475 · Cited by 537 · see citing works
Hollander, P., Gupta, A. K., Plodkowski, R., Greenway, F., Bays, H., Burns, C., Klassen, P., Fujioka, K., & for the COR-Diabetes Study Group (2013) · Diabetes Care · doi:10.2337/dc13-0234 · Cited by 501 · see citing works
Association Between Bariatric Surgery and Long-term Survival
Arterburn, D. E., Olsen, M. K., Smith, V. A., Livingston, E. H., Van Scoyoc, L., Yancy, W. S., Eid, G., Weidenbacher, H., & Maciejewski, M. L. (2015) · JAMA · doi:10.1001/jama.2014.16968 · Cited by 479 · see citing works
Reassessing human adipose tissue
Cypess, A. M. (2022) · New England Journal of Medicine · doi:10.1056/nejmra2032804 · Cited by 404 · see citing works
Direct medical costs of obesity in the United States and the most populous states
Cawley, J., Biener, A., Meyerhoefer, C., Ding, Y., Zvenyach, T., Smolarz, B. G., & Ramasamy, A. (2021) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2021.20410 · Cited by 400 · see citing works
Association of Bariatric Surgery With Cancer Risk and Mortality in Adults With Obesity
Aminian, A., Wilson, R., Al-Kurd, A., Tu, C., Milinovich, A., Kroh, M., Rosenthal, R. J., Brethauer, S. A., Schauer, P. R., Kattan, M. W., et al. (2022) · JAMA · doi:10.1001/jama.2022.9009 · Cited by 357 · see citing works
Indirect costs of obesity: a review of the current literature
Trogdon, J. G., Finkelstein, E. A., Hylands, T., Dellea, P. S., & Kamal‐Bahl, S. J. (2008) · Obesity Reviews · doi:10.1111/j.1467-789x.2008.00472.x · Cited by 324 · see citing works
Aronne, L. J., Wadden, T. A., Peterson, C., Winslow, D., Odeh, S., & Gadde, K. M. (2013) · Obesity · doi:10.1002/oby.20584 · Cited by 274 · see citing works
Utility of hemoglobin A1c in predicting diabetes risk
Edelman, D., Olsen, M. K., Dudley, T. K., Harris, A. C., & Oddone, E. Z. (2004) · Journal of General Internal Medicine · doi:10.1111/j.1525-1497.2004.40178.x · Cited by 213 · see citing works
Wadden, T. A., Tronieri, J. S., Sugimoto, D., Lund, M. T., Auerbach, P., Jensen, C., & Rubino, D. (2020) · Obesity · doi:10.1002/oby.22726 · Cited by 200 · see citing works
Garvey, W. T., Birkenfeld, A. L., Dicker, D., Mingrone, G., Pedersen, S. D., Satylganova, A., Skovgaard, D., Sugimoto, D., Jensen, C., & Mosenzon, O. (2020) · Diabetes Care · doi:10.2337/dc19-1745 · Cited by 186 · see citing works
Madigan, C. D., Graham, H., Sturgiss, E. A., Kettle, V. E., Gokal, K., Biddle, G. J. H., Taylor, G. M. J., & Daley, A. (2022) · BMJ · doi:10.1136/bmj-2021-069719 · Cited by 121 · see citing works
Cardel, M. I., Newsome, F. A., Pearl, R. L., Ross, K. M., Dillard, J. R., Miller, D. R., Hayes, J. F., Wilfley, D. E., Keel, P. K., Dhurandhar, E. J., et al. (2022) · Journal of the Academy of Nutrition and Dietetics · doi:10.1016/j.jand.2022.01.004 · Cited by 118 · see citing works
Vallis, M. (2016) · International Journal of Clinical Practice · doi:10.1111/ijcp.12765 · Cited by 84 · see citing works
A Heavy Burden: The Individual Costs of Being Overweight and Obese in the United States
Ferguson, C. C. (2010) · Cited by 65 · see citing works
Crockett, K. B., Borgatti, A. C., Tan, F., Tang, Z., & Dutton, G. R. (2021) · International Journal of Behavioral Medicine · doi:10.1007/s12529-021-10009-x · Cited by 6 · see citing works
Kosiborod, M., Bhatta, M., Davies, M. J., Deanfield, J. E., Garvey, T., Khalid, U., Kushner, R. F., Rubino, D., Zeuthen, N., & Verma, S. (2021) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(21)02982-x · Cited by 2 · see citing works
Barbero (2014) · doi:10.1016/j · Cited by 1 · see citing works
Flagged first, then by citations
Research works printed but not linked: 2
- [1]1. Kastanias P, Mackenzie K, Robinson S, Wang W. Medical complications resulting from severe obesity. In: Sockalingam S, Hawa R, eds. Psychiatric Care in Severe Obesity: An Interdiscliplinary Guide to Integrated Care. Springer; 2016:49-73.
- [34]34. Rind D, Guzauskas G, Fazioli K, et al. Oral semaglutide for type 2 diabetes: Effectiveness and value. Institute for Clinical and Economic Review. December 9, 2019. Accessed May 10, 2022. https:// icer.org/wp-content/uploads/2020/10/ ICER_Diabetes_Final-Evidence- Report_120919-1.pdf
Cited by
Sorted by citations
Mozaffarian, D., Agarwal, M., Aggarwal, M., Alexander, L., Apovian, C. M., Bindlish, S., Bonnet, J., Butsch, W. S., Christensen, S., Gianos, E., et al. (2025) · The American Journal of Clinical Nutrition · doi:10.1016/j.ajcnut.2025.04.023 · Cited by 154 · see citing works
“In non-industry sponsored analyses, net costs per quality-adjusted life year have ranged from $237,000-$483,000 [79], with low cost-effectiveness related to plateauing of weight benefits but continued costs of treatment, as well as weight regain following any cessation of use.”
Mozaffarian, D., Agarwal, M., Aggarwal, M., Alexander, L., Apovian, C. M., Bindlish, S., Bonnet, J., Butsch, W. S., Christensen, S., Gianos, E., et al. (2025) · Obesity · doi:10.1002/oby.24336 · Cited by 143 · see citing works
GLP-1 agonists for obesity—A new recipe for success
Mozaffarian, D. (2024) · JAMA · doi:10.1001/jama.2024.2252 · Cited by 76 · see citing works
Effectiveness and safety of drugs for obesity
Henderson Lewis, K., Sloan, C. E., Bessesen, D. H., & Arterburn, D. (2024) · BMJ · doi:10.1136/bmj-2022-072686 · Cited by 66 · see citing works
A cost comparison of GLP-1 receptor agonists and bariatric surgery: what is the break even point?
Docimo, S., Shah, J., Warren, G., Ganam, S., Sujka, J., & DuCoin, C. (2024) · Surgical Endoscopy · doi:10.1007/s00464-024-11191-1 · Cited by 46 · see citing works
Cost-Effectiveness of Antiobesity Drugs for Adolescents With Severe Obesity
Mital, S., & Nguyen, H. V. (2023) · JAMA Network Open · doi:10.1001/jamanetworkopen.2023.36400 · Cited by 41 · see citing works
Genetic and physiological insights into satiation variability predict responses to obesity treatment
Cifuentes, L., Añazco, D., O’Connor, T., Hurtado, M. D., Ghusn, W., Campos, A., Fansa, S., MCRAE, A. N., Madhusudhan, S., Kolkin, E., et al. (2025) · Cell Metabolism · doi:10.1016/j.cmet.2025.05.008 · Cited by 29 · see citing works
Mozaffarian, D., Agarwal, M., Aggarwal, M., Alexander, L., Apovian, C. M., Bindlish, S., Bonnet, J., Butsch, W. S., Christensen, S., Gianos, E., et al. (2025) · Obesity Pillars · doi:10.1016/j.obpill.2025.100181 · Cited by 28 · see citing works
Factors Associated With Semaglutide Initiation Among Adults With Obesity
Podolsky, M. I., Raquib, R., Shafer, P. R., Hempstead, K., Ellis, R. P., & Stokes, A. C. (2025) · JAMA Network Open · doi:10.1001/jamanetworkopen.2024.55222 · Cited by 26 · see citing works
Mamas, M. A., Bays, H., Li, R., Upadhyay, N., Irani, T., Senyucel, C., Dunn, J. P., & Liu-Seifert, H. (2025) · European Heart Journal Open · doi:10.1093/ehjopen/oeaf117 · Cited by 24 · see citing works
Mozaffarian, D., Agarwal, M., Aggarwal, M., Alexander, L., Apovian, C. M., Bindlish, S., Bonnet, J. P., Butsch, W. S., Christensen, S. M., Gianos, E., et al. (2025) · Obesity Pillars · doi:10.1016/j.obpill.2026.100269 · Cited by 26 · see citing works
Medicare Part D Coverage of Anti-obesity Medications: a Call for Forward-Looking Policy Reform
Hernandez, I., Wright, D. R., Guo, J., & Shrank, W. H. (2024) · Journal of General Internal Medicine · doi:10.1007/s11606-023-08416-9 · Cited by 18 · see citing works
Sallam, M., Snygg, J., Ghandour, S. E., & Sallam, M. (2025) · Obesities · doi:10.3390/obesities5020026 · Cited by 18 · see citing works
Brosnihan, P., Luce, M. S., Yetasook, A. K., Perez, C., Scharf, K. R., & Aly, S. (2025) · The American Surgeon™ · doi:10.1177/00031348251337145 · Cited by 17 · see citing works
High price and demand for semaglutide means lack of access for US patients
Brown, C. (2023) · BMJ · doi:10.1136/bmj.p1863 · Cited by 15 · see citing works
Shifting paradigms: Reframing coverage of antiobesity medications for plan sponsors
Green, L., & Taddei-Allen, P. (2023) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2023.29.5.564 · Cited by 12 · see citing works
Yao, Z., Tchang, B. G., Chae, K., Albert, M. H., Clark, J. M., & Blaha, M. J. (2025) · Journal of Internal Medicine · doi:10.1111/joim.20083 · Cited by 9 · see citing works
The National Psoriasis Foundation Primer on GLP-1 Receptor Agonists in Psoriasis
Sheth, S., Merola, J. F., Weber, B. N., Prussick, R. B., Yeung, J., Liu, C., Glick, B. P., Reddy, S. M., Cook-Bolden, F. E., Wallace, E. B., et al. (2026) · JAMA Dermatology · doi:10.1001/jamadermatol.2026.0859 · Cited by 12 · see citing works
Haggerty, T. S., Dekeseredy, P., Bailey, J., Cowher, A. E., Baus, A., & Davisson, L. (2024) · Obesity Pillars · doi:10.1016/j.obpill.2024.100120 · Cited by 8 · see citing works
Katsarou, A., Kouvari, M., Hill, M. A., & Mantzoros, C. S. (2023) · Metabolism · doi:10.1016/j.metabol.2023.155714 · Cited by 6 · see citing works
Cost-Effectiveness of Semaglutide for Secondary Prevention of Cardiovascular Disease in US Adults
Hennessy, S. S., Penko, J. M., Bellows, B. K., Coxson, P. G., Boylan, R. D., Sims, K. D., Beatty, A. L., Inoue, K., Shi, I., Decker, S. R. D. R., et al. (2026) · JAMA Cardiology · doi:10.1001/jamacardio.2025.5243 · Cited by 5 · see citing works
Older Adults’ Views on Insurance Coverage for Weight Management Medications
Oshman, L. D., Kirch, M., Solway, E. S., Singer, D., Malani, P., Roberts, J. S., Kullgren, J. T., & Hafez, D. (2025) · JAMA Network Open · doi:10.1001/jamanetworkopen.2025.2008 · Cited by 5 · see citing works
Brown, A., & Chhabra, K. R. (2024) · Annals of Surgery · doi:10.1097/sla.0000000000006583 · Cited by 5 · see citing works
The Real-World Costs of GLP-1 Receptor Agonist TreatmentPreprint
Wennberg, D. E., Coetzer, H., Marr, A. L., Margiotta, C., Hashmi, R., Kay, J., Vats, V., Hagen, S., Anatale‐Tardiff, L., Rao, S., et al. (2025) · medRxiv · doi:10.1101/2025.10.24.25338255 · Cited by 4 · see citing works
Burns, R. B., Jay, M. R., Thorndike, A. N., & Kanjee, Z. (2024) · Annals of Internal Medicine · doi:10.7326/annals-24-01740 · Cited by 2 · see citing works
McDonough, D. J. (2025) · Physiologia · doi:10.3390/physiologia5010010 · Cited by 2 · see citing works
Challenges in Modelling the Cost Effectiveness of Pharmacotherapies for Obesity
Pennington, B., Cummins, E., Chandler, A., & Fotheringham, J. (2025) · PharmacoEconomics · doi:10.1007/s40273-025-01520-0 · Cited by 2 · see citing works
Rothberg, A. E., Ye, W., Miller, N., & Rizza, R. A. (2025) · Obesity Science & Practice · doi:10.1002/osp4.70092 · Cited by 1 · see citing works
Response to Fitch and Huett‐Garcia
Gasoyan, H., Pfoh, E. R., Schulte, R. J., Le, P., & Rothberg, M. B. (2024) · Obesity · doi:10.1002/oby.24039
Dellgren, J. L., Emanuel, E., & Persad, G. (2024) · JAMA · doi:10.1001/jama.2024.12068
Monroy, R. H., Rivera, M. E. C., & Marielarena, R. R. F. (2025) · Acta Médica Grupo Ángeles · doi:10.35366/122158
Beyond Diabetes: A Review of Emerging Indications for Glucagon-Like Peptide-1 Receptor Agonists
West, L. M., Patolia, H. H., Chapman, B., Laffin, L. J., Vest, A. R., Sauer, A. J., & Martyn, T. (2026) · Reviews in Cardiovascular Medicine · doi:10.31083/rcm44528
Comprehensive Lifestyle Intervention as Primary Therapy for Obesity: A Case Study
Manna, J., & Cutt, A. (2026) · American Journal of Lifestyle Medicine · doi:10.1177/15598276261435489
GLP-1 Prescriptions for Weight Loss by Differences in Insurance Plan Coverage
Shahzad, M., Advani, P., Akintola, O., & CHERNEW, M. (2026) · JAMA Health Forum · doi:10.1001/jamahealthforum.2026.1838
- Authors
- Atlas, S. J., Kim, K., Nhan, E., Touchette, D. R., Moradi, A., Agboola, F., Rind, D. M., Beaudoin, F. L., & Pearson, S. D.
- Affiliations
- Harvard University (US)
- University of Illinois Chicago (US)
- Institute for Clinical and Economic Review (US)
- Brown University (US)
- ORCID
- Venue
- Journal of Managed Care & Specialty Pharmacy
- Publisher
- Academy of Managed Care Pharmacy
- Published
- 2023-05
- Volume
- 29
- Issue
- 5
- Pages
- 569-575
- ISSN
- 2376-0540 (ISSN-L)
- 2376-1032
- PMC
- PMC10387935
- OpenAlex
- W4367549965
- Cited by
- 33
- References
- 39
- Citations by year
- 2026: 5 · 2025: 15 · 2024: 8 · 2023: 5
- FWCI
- 5.14
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Journal of Managed Care & Specialty Pharmacy (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Surgery › Bariatric Surgery and Outcomes
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Obesity, Physical Activity, Diet
- Keywords
- obesity, anti-obesity drugs, drug effectiveness, value of care, managed care, specialty pharmacy
- MeSH terms
- Humans, Obesity, Anti-Obesity Agents
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
